NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, SINGAPORE, SOUTH AFRICA OR NEW ZEALAND OR IN ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OF THIS PRESS RELEASE WOULD BE UNLAWFUL. Following the end of the subscription period, the results of Active Biotech's rights issue show that 14,736,623 shares, corresponding to approximately 98.3 percent of the shares offered, were subscribed for with subscription rights. In addition thereto 3,857,742 shares, corresponding to approximately 26 percent of the shares offered, were subscribed for without subscription rights. The rights issue was thereby oversubscribed with approximately 24 percent. The shares that were subscribed for without subscription rights have been allotted to the subscribers in accordance with the principles outlined in the prospectus. Notification regarding such allocation is only sent to those who have been allotted shares. Through the rights issue, Active Biotech will receive proceeds amounting to approximately SEK 225 million, before issue costs. Furthermore, Active Biotech's share capital increases through the rights issue by approximately SEK 56,482,529.18 to approximately SEK 338,895,182.64 and the total number of shares increases by 14,984,716 to 89,908,298 shares. The new shares are expected to be registered with the Swedish Companies Registration Office on or about January 16, 2015 and trading in the new shares on Nasdaq Stockholm is expected to commence on or about January 27, 2015. For further information, please contact: Tomas Leanderson, CEO Tel: +46 (0)46 19 20 95 E-mail: tomas.leanderson@activebiotech.com Hans Kolam, CFO Tel: +46 (0)46 19 20 44 E-mail: hans.kolam@activebiotech.com Active Biotech AB (publ) (Nasdaq Stockholm: ACTI) is a biotechnology company with focus on neurodegenerative diseases and cancer. Projects in pivotal phase are laquinimod, an orally administered small molecule with unique immunomodulatory properties for the treatment of multiple sclerosis, and tasquinimod, an oral immunomodulatory, anti-metastatic substance for the treatment of prostate cancer. The objective of the preclinical ISI project is to produce new, patentable chemical compounds for treatment of diseases in the company's focus areas. Please visit www.activebiotech.com for more information. Active Biotech is required to publish the information contained in this press release in accordance with the Swedish Securities Market Act. This information was provided to the media for publication at 3.30 pm CET on December 29, 2014. Important information This press release is not an offer to subscribe for shares in Active Biotech. A prospectus relating to the rights issue referred to in this press release has been made public prior to the commencement of the subscription period. This press release is not a prospectus and investors should not subscribe for or purchase any securities, except on the basis of information provided in the prospectus. This press release may not be made public, released or distributed, directly or indirectly, in or into the United States, Australia, Hong Kong, Japan, Canada, Singapore, South Africa or New Zealand or in any other jurisdiction in which the distribution of this press release would be unlawful. Further, this press release does not constitute an offer to sell new shares, paid subscribed for shares ("BTA") or subscription rights to any person in any jurisdiction in which it is unlawful to make such offer to such person or where such action would require additional prospectuses, registration or other measures other than those pursuant to Swedish law. The prospectus, application form and other documents associated with the rights issue may not be distributed in or to any country where such distribution or the rights issue would require such measures set forth in the preceding sentence or be in violation of the regulations of such country. The new shares, BTAs and subscription rights have not been recommended by a United States federal or state securities commission or regulatory authority. No new shares, BTAs, subscription rights or other securities issued by Active Biotech have been or will be registered under the U.S. Securities Act of 1933, or under the securities legislation in any state of the United States or any province in Canada. Accordingly, no new shares, BTAs, subscription rights or other securities issued by Active Biotech may be transferred or offered for sale in the United States or Canada, other than in such exceptional cases that do not require registration. The securities issued in the rights issue will not be offered to the public in the United States. Active Biotech has not authorized any offer of securities to the public in any country in the European Economic Area ("EEA") other than Sweden. In other member states in the EEA which have implemented the Directive 2003/71/EC (the "Prospectus Directive") (each, a "Relevant Member State"), no action has been undertaken and will not be undertaken to make an offer of securities to the public requiring publication of a prospectus in any Relevant Member State. As a result, the securities may only be offered in Relevant Member States to (a) any legal entity which is a qualified investor as defined in the Prospectus Directive; or (b) any person falling within Article 3(2) of the Prospectus Directive. The rights issue is only directed at (i) persons who are outside the United Kingdom or (ii) persons who have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "Order") and (iii) high net worth entities, and other persons to whom it may lawfully be communicated, falling within Article 49(2) of the Order (all such persons together being referred to as "relevant persons"). The securities issued in the rights issue will only be available to and will only be engaged with, relevant persons. Any person who is not a relevant person should not act or rely on this document or any of its contents. [HUG#1883710]
Active Biotech's rights issue of approximately SEK 225
Top 10 Most Recent News Articles
Ave7® Pioneers AI-Driven Marketplace Evolution
AI Reshapes the Agency Paradigm Nobody saw this coming a decade ago, but here we are—AI's taking the wheel, but with humans still riding shotgun. The agency world, particularly the one dealing with e-commerce giants like Amazon, Walmart, and Target, has flipped on its head. Ave7® steps up as the frontrunner, adapting faster than a broker's reflex after a market bell....
Continue Reading
Flexible Packaging Market to Hit $384.32B by 2031
Packaging's Flexible Future Alright, here's the skinny: you might want to adjust those portfolios if you're watching the materials sector, because the flexible packaging market ain't just loosening up—it's stretching out like never before. By 2031, we're talking about it raking in a solid $384.32 billion, climbing from $313.25 billion in 2026. That's a not-so-shabby...
Continue Reading
Exploring Creation: A Fresh Look at Genesis
Opening Up Genesis in a New Light Hey, if you’re like most folks, you’ve probably heard Genesis framed as the battleground for science versus religion debates, right? Enter into this mix a fresh take with Robert E. Franzen’s new book, The Narration of Creation. This book asks you to overlook those grand philosophical fights and instead focus on the narrative itself....
Continue Reading
Giovanni Recalde Sues County After False Report
Justice and Reputation: A Mix-Up Costs Big When the cops screw up, sometimes they really take the cake. That's what Giovanni Recalde learned, the hard way, when his name got tangled in a mess related to a gambling operation he wasn't even a part of. Prince William County police pasted his name into their daily incident report last year like it was no big deal. But it...
Continue Reading
Gwen Stefani Kicks Off OCVIBE's New Concert Hall
A Homecoming Steeped in Nostalgia Orange County’s about to do a serious throwback, folks! Gwen Stefani is set to headline the opening concert at OCVIBE's spanking new concert hall in Anaheim on March 17, 2027. Curious choice for their opener? Hardly. This gal's practically woven into the county’s tapestry—her roots run deep here, enough to make even the casual music...
Continue Reading
Mall of America Strives for World Record This Black Friday
History in the Making at Mall of America Yeah, it seems these folks are not just about shopping anymore. The Mall of America is aiming to set the bar high this Black Friday, eyeing a GUINNESS WORLD RECORDS title for the most people holding up the same shopping bag all at once. Imagine a thousand people, synchronized like a flash mob—only with shopping bags instead of...
Continue Reading
IQSTEL's Nine-Month Revenue Hits $313M, Growth Impresses
Pushing Through With Persistence Well, well, well, here we are, talking about IQSTEL Inc. (NASDAQ: IQST) slinging some serious numbers—not the kind you can ignore at your breakfast table. The company pulled in a whopping $313 million in revenue over the first nine months of 2026. That’s a bump up by 34.5% from last year’s $232.7 million. What’s behind the magic...
Continue Reading
Tenax Therapeutics Facing Class Action: DEC 28 Deadline
Legal Storm Over Tenax Therapeutics Just what the doctor didn't order—legal headaches for Tenax Therapeutics, Inc. (NASDAQ:TENX). Yup, folks, buckle up because we're diving into another class action mudslinging match that’s setting the markets wagging. Berger Montague's law trebuchet is aimed squarely at Tenax and every investor should know the target’s outline....
Continue Reading
Dawson Struggles With Q3 Losses Despite Growth Prospects
Profit and loss dance around like a jittery stock, and Dawson Geophysical is feeling the heat this third quarter. Numbers are in, and we’re seeing a net loss of $5.2 million, translating to $0.17 per share—ouch. Not to mention a negative Adjusted EBITDA of $2 million. Compared to last year's hopes, that's a serious belly flop. Revenue Down, Hopes Up In a fetching...
Continue Reading
Disney+ Teams Up with Tiff's: Blue Cookie Debut
A Sweet Collaboration on the Horizon If somebody had told me that cookies could conjure up excitement equivalent to a TV show's new season, I'd have laughed. But here we are—Disney+ and Tiff's Treats are cooking up a storm with blue chocolate chip cookies to celebrate 'Percy Jackson and the Olympians' Season 3 premiere. The Cookie That Packs a Punch Forget ordinary...
Continue ReadingTop 5 Most Recently Viewed Articles
BARROT Showcases Groundbreaking Bluetooth Innovations at CES
BARROT Introduces Innovative Bluetooth Technologies at CES 2025 At CES 2025, held in Las Vegas, BARROT, a prominent name in short-range wireless communication, proudly showcased its latest advancements in Bluetooth technology. The highlight of BARROT's presentation is its Bluetooth v6.0-qualified stack, which integrates various cutting-edge wireless solutions including...
Continue Reading
Explore Summer Adventures Awaiting in Myrtle Beach's Shores
Experience Unforgettable Summer Days in Myrtle Beach There's still plenty of time to enjoy a sun-soaked getaway the whole family will love. The sun is shining, the days are stretching on, and there remains an abundance of summer left to indulge in cherished family adventures along the beautiful coastline of Myrtle Beach. Whether you're meticulously planning your escape or...
Continue Reading
NextNRG Surges Ahead with Impressive Growth Metrics and Strategy
NextNRG Achieves Extraordinary Revenue Growth AI-Driven Energy Pioneer Delivers Sixth Consecutive Record Month Company on Clear Path to $100 Million Revenue Run-Rate with Canadian Acquisition NextNRG, Inc. (Nasdaq: NXXT) is shaping the future of energy with its innovative AI-driven solutions. Recently, the company announced outstanding preliminary financial results that...
Continue Reading
Insights on IES Hldgs's Increasing Short Interest
Understanding IES Hldgs's Current Short Interest Trends IES Hldgs has recently experienced a notable increase in its short interest, with the short percent of float rising by 11.11% since the last update. Investors should be aware that the latest figures indicate 673 thousand shares sold short, accounting for 7.6% of all regular trading shares. Given its current trading...
Continue Reading
ALINA Residences Celebrates Luxury VERIFIED™ Status Award
ALINA Residences: A New Victory in Luxury Living ALINA Residences, located in the heart of Boca Raton, recently snagged the spotlight with its shiny new VERIFIED™ Luxury Residences plaque from Forbes Travel Guide. To most, it might just seem like a piece of metal, but in the world of upscale living, this is a badge of honor. Celebrating Commitment to Service Excellence...
Continue Reading